



Medicine: tirbanibulin (brand name: Klisyri®)

Almirall

The Scottish Medicines Consortium (SMC) has assessed tirbanibulin for treating adults with actinic keratosis. It is an ointment used for treating mild actinic keratosis on the face and scalp. This document summarises the SMC decision and what it means for patients.

What has SMC said?

After careful consideration, SMC has accepted tirbanibulin for the treatment of actinic keratosis as described above.

What does SMC's decision mean for patients?

If your healthcare professional thinks that tirbanibulin for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland.



What is tirbanibulin used for?

Tirbanibulin is used to treat a skin condition called actinic keratosis, which is a pre-cancerous, rough scaly patch of skin that can develop after too much exposure to sunlight. It is most often found on the face or scalp.

How does tirbanibulin work?

Actinic keratosis is caused by cumulative sun damage, which leads to genetic changes in a specific type of skin cell (keratinocyte), causing them to divide at a faster rate than normal keratinocytes. Tirbanibulin binds to a protein called tubulin in the keratinocyte cells, which is important in cell division. By binding to tubulin, tirbanibulin helps to prevent the keratinocyte cells from multiplying and causes them to die.

How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- The potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of tirbanibulin by looking at the SMC Detailed Advice Document (SMC2395).

More information

The organisations below can provide more information and support for people with actinic keratosis and their families. SMC is not responsible for the content of any information provided by external organisations.

Melanoma Action and Support Scotland (MASScot)



<https://www.masscot.org.uk>



0773 823 1260

Melanoma UK



<https://www.melanomauk.org.uk>



0808 171 2455

You can find out more about tirbanibulin (Klisyri®) in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<https://www.ema.europa.eu/en>